We use cookies to give you the best possible experience on our website.

James E. Muller, MD

Director, VP2

Dr. James E. Muller is director the the CIMIT Vulnerable Plaque and Patient Program and a cardiologist at Brigham and Women's Hospital. From 2005 to 2015 Dr. Muller served as CEO and then Chief Medical Officer of Infraredx, Inc. a company he founded to develop an instrument to identify vulnerable coronary plaques.  With the sale of Infraredx to Nipro, Inc., he has returned to academic medicine to develop the full range of activities necessary to improve the prevention of heart attacks.

Infraredx, Inc, successfully developed a multimodality near-infrared spectroscopy and IVUS coronary catheter that can identify the lipid-rich and presumably vulnerable coronary artery plaques that cause heart attacks.  The definitive test of this technology -- an outcomes study in 1562 patients -- is expected to yield results in March, 2017. 

Dr. Muller formerly served as a Professor of Medicine at the Harvard Medical School where he conducted research for over 25 years on the causes of heart attacks. In 1994, with Drs. Stone and Tofler, he introduced the term "vulnerable plaque" to describe those plaques likely to disrupt and cause disease onset. Dr. Muller was one of three American Co-founders of the International Physicians for the Prevention of Nuclear War (IPPNW) the organization awarded the 1985 Nobel Peace Prize.

To learn more about the program please email Dr. Muller.